A reasonable question Zues. I am after a better understanding of the investment opportunity in USRM. I want my DD based on a true understanding of USRM's business. I'd like to weed through the mass of opinions on this board, some of which are well educated, while many others unfortunately are not.
I do own a good number of shares in USRM. I invested prior to the latest Form 8-K filing and the settlement with Northstar. This transaction with GAPC has raised a lot of questions in my mind. I simply want a better understanding of the results of the deal with GACP before I decide to add more to, or liquidate my USRM holdings.
I am not surprised that my questions have rankled a few feathers. But I believe my questions posted on this board are valid and therefore hopefully receive a well educated response. I know that legal documents can be long and difficult to understand, but I believe many on this board do not correctly understand what USRM has done with their agreement with GACP.
Would it change any investor's opinion of their USRM investment if it is true that USRM sold off their stem cell bank business (at least for the life of the lease with GAPC). I don't know enough about the existing and future profits generated from this part of the business. It might make good sense to jettison less important parts of the business and focus on the FDA products like MyoCell®, MyoCell SDF-1 and AdipoCell. Perhaps even a suitor doesn't want all the ancillary business units and only these products.
News 
Market Data 
Discover 
AI
